Goldman Sachs cut its price target on PMC-Sierra, Inc. (NASDAQ: PMCS) after the company cut its earnings estimates for Q3. It lowered its target to $10 from $11.
In the research note, Goldman writes, "PMC-Sierra preannounced its...(
read more)
PMC-Sierra, Inc. (NASDAQ: PMCS) released an update of its business outlook after the closing bell Tuesday, which traders didn't care for. Shares are now down by 6.29%, trading at $7.30 after ending the regular session higher by...(
read more)
Vical Inc. (NASDAQ: VICL) tumbled as much as 40% after partner Sanofi-Aventis (NYSE: SNY) announced that late stage trials of NV1FGF failed to meet its goal of preventing limb amputation or...(
read more)